Medlab Clinical (ASX:MDC) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Medlab Clinical's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Medlab Clinical could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Medlab Clinical's Cash-to-Debt or its related term are showing as below:

ASX:MDC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.24 Med: 7.93 Max: No Debt
Current: No Debt

During the past 8 years, Medlab Clinical's highest Cash to Debt Ratio was No Debt. The lowest was 1.24. And the median was 7.93.

ASX:MDC's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.39 vs ASX:MDC: No Debt

Medlab Clinical Cash-to-Debt Historical Data

The historical data trend for Medlab Clinical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Medlab Clinical Cash-to-Debt Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

11.14

3.88

7.93

4.62

No Debt

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												8.61	4.62	3.35	No Debt	No Debt

Competitive Comparison of Medlab Clinical's Cash-to-Debt

For the Biotechnology subindustry, Medlab Clinical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's Cash-to-Debt falls into.

Medlab Clinical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Medlab Clinical's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Medlab Clinical had no debt ⁽¹⁾.

Medlab Clinical's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Medlab Clinical had no debt ⁽¹⁾.

Medlab Clinical (ASX:MDC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Medlab Clinical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (ASX:MDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.